Mark M Smits1, Marcel H A Muskiet1, Lennart Tonneijck1, Trynke Hoekstra2,3, Mark H H Kramer1, Michaela Diamant1, Daniël H van Raalte1. 1. Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam. 2. Department of Health Sciences and the EMGO Institute for Health and Care Research, VU University Amsterdam, Amsterdam. 3. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands.
Abstract
AIM: Clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA) is consistently associated with heart rate (HR) acceleration in type 2 diabetes patients. We explored the mechanisms underlying this potential safety concern. METHODS:Ten healthy overweight males (aged 20-27 years) were examined in an open label, crossover study. Automated oscillometric blood pressure measurements and finger photoplethysmography were performed throughout intravenous administration of placebo (saline 0.9%), exenatide (targeting therapeutic concentrations) and a combination of exenatide and the nitric oxide synthase inhibitor L-N(G) -monomethyl arginine (L-NMMA). Sympathetic nervous system (SNS) activity was measured by heart rate variability and rate-pressure product. RESULTS:Exenatide increased HR by a mean maximum of 6.8 (95% CI 1.7, 11.9) beats min(-1) (P < 0.05), systolic blood pressure (SBP) by 9.8 (95% CI 3.5, 16.1) mmHg (P < 0.01) and markers of SNS activity (P < 0.05). No changes in total peripheral resistance were observed. Increases in HR, SBP and sympathetic activity were preserved during concomitant L-NMMA infusion. CONCLUSIONS: Our data argue against exenatide-induced reflex tachycardia as a response to vasodilation and rather suggest the involvement of SNS activation in humans.
RCT Entities:
AIM: Clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA) is consistently associated with heart rate (HR) acceleration in type 2 diabetespatients. We explored the mechanisms underlying this potential safety concern. METHODS: Ten healthy overweight males (aged 20-27 years) were examined in an open label, crossover study. Automated oscillometric blood pressure measurements and finger photoplethysmography were performed throughout intravenous administration of placebo (saline 0.9%), exenatide (targeting therapeutic concentrations) and a combination of exenatide and the nitric oxide synthase inhibitor L-N(G) -monomethyl arginine (L-NMMA). Sympathetic nervous system (SNS) activity was measured by heart rate variability and rate-pressure product. RESULTS:Exenatide increased HR by a mean maximum of 6.8 (95% CI 1.7, 11.9) beats min(-1) (P < 0.05), systolic blood pressure (SBP) by 9.8 (95% CI 3.5, 16.1) mmHg (P < 0.01) and markers of SNS activity (P < 0.05). No changes in total peripheral resistance were observed. Increases in HR, SBP and sympathetic activity were preserved during concomitant L-NMMA infusion. CONCLUSIONS: Our data argue against exenatide-induced reflex tachycardia as a response to vasodilation and rather suggest the involvement of SNS activation in humans.
Authors: L W J Bogert; K H Wesseling; O Schraa; E J Van Lieshout; B A J M de Mol; J van Goudoever; B E Westerhof; J J van Lieshout Journal: Anaesthesia Date: 2010-09-21 Impact factor: 6.955
Authors: Magnus T Jensen; Jacob L Marott; Kristine H Allin; Børge G Nordestgaard; Gorm B Jensen Journal: Eur J Prev Cardiol Date: 2011-04-27 Impact factor: 7.804
Authors: Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Daniël H van Raalte; Michaela Diamant Journal: Lancet Diabetes Endocrinol Date: 2014-08-10 Impact factor: 32.069
Authors: Frauke Fehse; Michael Trautmann; Jens J Holst; Amy E Halseth; Nuwan Nanayakkara; Loretta L Nielsen; Mark S Fineman; Dennis D Kim; Michael A Nauck Journal: J Clin Endocrinol Metab Date: 2005-09-06 Impact factor: 5.958
Authors: Marc A Pfeffer; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars V Køber; Francesca C Lawson; Lin Ping; Xiaodan Wei; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif Journal: N Engl J Med Date: 2015-12-03 Impact factor: 91.245
Authors: Mark M Smits; Marcel H A Muskiet; Lennart Tonneijck; Trynke Hoekstra; Mark H H Kramer; Michaela Diamant; Daniël H van Raalte Journal: Br J Clin Pharmacol Date: 2016-01-25 Impact factor: 4.335
Authors: Lennart Tonneijck; Mark M Smits; Marcel H A Muskiet; Trynke Hoekstra; Mark H H Kramer; A H Jan Danser; Michaela Diamant; Jaap A Joles; Daniël H van Raalte Journal: Diabetologia Date: 2016-04-01 Impact factor: 10.122